Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of the shareholders of SciClone Pharmaceuticals, Inc. (“SciClone” or the “Company”) (NASDAQ:SCLN) concerning possible violations of federal securities laws. SciClone engages in the development and commercialization of therapeutics for the treatment of cancer and infectious diseases in the People’s Republic of China and internationally. The Company’s principal product is ZADAXIN, which, among other things, is used for the treatment of hepatitis B and hepatitis C viruses and certain cancers.

The investigation focuses on allegations that certain statements made by the Company concerning SciClone’s business and operations were materially false and/or misleading. On August 9, 2010, SciClone disclosed that the U.S. Securities and Exchange Commission (SEC) has initiated a formal investigation of SciClone, and that the U.S. Department of Justice (DOJ) has requested that the Company meet with the DOJ regarding SciClone’s compliance with the Foreign Corrupt Practices Act (FCPA). In connection with its investigation, the SEC issued a subpoena to SciClone requesting a variety of documents relating to a range of matters including interactions with regulators and government-owned entities in China, activities relating to sales in China, and documents relating to certain Company financial and other disclosures.

If you are a shareholder of SciClone, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, Toll Free at (888) 638-4847, or by email to, or visit our website at

Copyright Business Wire 2010